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Abstract
Background: β-Mannosidosis (OMIM 248510) is a rare inborn lysosomal storage disorder caused
by the deficient activity of β-mannosidase, an enzyme encoded by a single gene (MANBA) located
on chromosome 4q22-25. To date, only 20 cases of this autosomal recessive disorder have been
described and 14 different MANBA mutations were incriminated in the disease. These are all null
mutations or missense mutations that abolish β-mannosidase activity. In this study, we
characterized the molecular defect of a new case of β-mannosidosis, presenting with a severe
neurological disorder.
Methods: Genomic DNA was isolated from peripheral blood leukocytes of the patient to allow
MANBA sequencing. The identified mutation was engineered by site-directed mutagenesis and the
mutant protein was expressed through transient transfection in HEK293T cells. The β-
mannosidase expression and activity were respectively assessed by Western blot and fluorometric
assay in both leukocytes and HEK293T cells.
Results: A missense disease-associated mutation, c.1922G>A (p.Arg641His), was identified for
which the patient was homozygous. In contrast to previously described missense mutations, this
substitution does not totally abrogate the enzyme activity but led to a residual activity of about 7%
in the patient's leukocytes, 11% in lymphoblasts and 14% in plasma. Expression studies in
transfected cells also resulted in 7% residual activity.
Conclusion: Correlations between MANBA mutations, residual activity of β-mannosidase and the
severity of the ensuing neurological disorder are discussed. Whether the c.1922G>A mutation is
responsible for a yet undescribed pseudodeficiency of β-mannosidase is also discussed.
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Background
β-Mannosidosis (OMIM 248510) is a rare autosomal
recessive disease due to the deficient activity of acid β-
mannosidase, a lysosomal hydrolase involved in the ter-
minal catabolism of glycoproteins [1-3]. It is characterized
by intralysosomal accumulation of (di)saccharides.
Despite the low number of human cases reported so far
(21 cases in 17 families including this study), a wide range
of symptoms of varying degree of severity is observed [2,4-
19]. The disease was first described in ruminants
[1,20,21], where the enzyme defect is associated with a
severe neurological phenotype including demyelination,
skeletal deformation, facial dysmorphism and neonatal
death. The human disease is generally of milder severity
and with a later onset. Whereas mental retardation,
behavioural abnormalities and hearing loss are frequently
observed, facial dysmorphism, skeletal deformation, sus-
ceptibility to respiratory infections and skin lesions have
only been reported in a few patients.
In this study, we analyzed the molecular defect underlying
a new case of deficient activity of β-mannosidase with
marked involvement of pyramidal and cerebellar path-
ways, a clinical spectrum that has not previously been
reported in β-mannosidosis. A missense mutation in the
MANBA gene was identified. This is the first report of a
MANBA missense mutation present at the homozygous
state and which retains a residual activity while being
associated with a severe neurological disease.
Methods
Case report
The clinical presentation of the case has been reported
elsewhere [22]. Briefly, the patient was born to Algerian
consanguineous (first cousins) parents. Mental retarda-
tion was observed since the age of 4. Spastic tetraparesis
and cerebellar ataxia were noted at age 12, along with vis-
ual and hearing deficits. Symptoms progressively wors-
ened and, at age 26, the patient suffered from tetraplegia,
dysphagia and dysarthria. Brain MRI showed a striking
cortical and subcortical atrophy while there was no
noticeable demyelination. Skin lesions and skeletal defor-
mations were absent. Siblings were asymptomatic. Writ-
ten informed consent was obtained from the patient's
father for the studies described below and for publication
of the study, according to the protocols approved by the
ethics review board of the Toulouse Hospital. Research
was performed in compliance with the Declaration of
Helsinki.
Enzyme assays
β-Mannosidase activity in peripheral blood leukocytes,
cultured lymphoid cells, plasma and HEK293T cells was
assessed using 4-methylumbelliferyl-β-D-mannopyrano-
side (Sigma, St Quentin Fallavier, France) as previously
described [12]. Acid β-galactosidase and E. coli β-galactos-
idase activities were determined using the 4-methylum-
belliferyl-β-D-galactopyranoside substrate (Sigma).
Briefly, cell lysates were incubated in the presence of 0.4
mg/mL of substrate at acidic (0.1 M sodium acetate buffer,
pH 4.5) or neutral (0.1 M Tris/HCl buffer, pH 7.0) pH for
determining acid, lysosomal β-galactosidase and E. coli β-
galactosidase activities, respectively. For the bacterial
enzyme (the activity of which is cation-dependent), assays
were performed either in the presence of 4 mM EDTA or
10 mM MgCl2, and the activity was calculated by subtract-
ing the value obtained in the presence of the chelator from
that obtained in the presence of MgCl2. Protein concentra-
tion was determined using the bicinchoninic acid protein
assay (Sigma).
Molecular analyses
Genomic DNA was isolated from peripheral blood leuko-
cytes (Nucleospin II, Macherey-Nagel, Germany). Exons 1
through 17 of the MANBA gene including intron-exon
junctions were individually amplified and sequenced in
both directions using previously described primers [23].
For cDNA analysis, RNA was isolated from Epstein-Barr
virus-transformed lymphoid cells (SV Total RNA extrac-
tion kit, Promega), reverse-transcribed and amplified
using previously reported primers [23]. DNA sequencing
was performed using an ABI3100 Applied Biosystems
automatic sequencer. For restriction enzyme analysis of
exon 14, amplicons were incubated with MaeIII or BbvI
(Roche Diagnostics, Germany, and New England Biolabs,
MA, respectively), and analysed on a 1.8% agarose gel.
Exon 14 from 200 control subjects, corresponding to 61
Finnish, 57 Norwegian, 35 North-African, 18 Hondurian,
15 Palestinian, and 14 Polish control individuals (ano-
nymized blood-donors), was PCR-amplified and
sequenced in the forward direction as previously
described [23]. The programs SIFT http://sift.jcvi.org/ and
PolyPhen http://genetics.bwh.harvard.edu/pph/ were
used for evaluation of the p.Arg641His substitution.
Site-directed mutagenesis of the human MANBA cDNA
The pCS2-MANBA-WT plasmid was kindly provided by
Dr. T. Beccari [24]. This construct was used as template for
site-directed mutagenesis using the QuickChange Site-
Directed Mutagenesis Kit (Stratagene) and primer pairs
(Forward primer 5' CTACCGCCGTAGTCACAGCGAGAT-
AGTGG 3' and Reverse primer 5' CCACTATCTCGCTGT-
GACTACGGCGGTAG 3') to introduce the c.1922G>A
mutation and to create the pCS2-MANBA-p.Arg641His
expression construct. The recombinant vector was puri-
fied (Qiagen Plamid Maxi kit) and the insert sequenced
using the following primers: 5' GCAAATGGGCGTTC-
CATTG 3', 5' ACTGCCCTCCACTTGTGC 3', 5' GTGGAT-
GCTAATATGAATAC 3', 5' CATCACGAAGGTGGTAAC 3',
and 5' GACCAACTACCACTTCTTG 3'.BMC Medical Genetics 2009, 10:84 http://www.biomedcentral.com/1471-2350/10/84
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Cell lines and transfections
Human embryonic kidney cells (HEK293T) were grown
in a humidified 5% CO2 atmosphere at 37°C in DMEM
containing Glutamax (2 mM), penicillin (100 U/ml),
streptomycin (100 μg/ml) and 10% heat-inactivated FCS.
Cells were transfected using Superfect (Qiagen) with 1 μg
of pCMV-LacZ plasmid and 5 μg of either pCS2-MANBA
or pCS2-MANBA-p.Arg641His plasmid. After 48 hours
incubation, cells were washed with PBS, harvested and
cell pellets were frozen at -80°C until use. Cells were lysed
in water, and enzyme activities were determined as
described above. For Western-blot analyses, cells were
lysed in lysis buffer (Cell Signaling) containing 1 mM
PMSF and a protease inhibitor cocktail (Complete,
Roche).
Western Blot analyses
Cell lysates were separated using a 7.5% SDS-polyacryla-
mide gel and transferred to a nitrocellulose membrane
(Bio-Rad). Proteins were detected using an ECL detection
system (Pierce). β-Mannosidase was detected by using a
mouse polyclonal antibody (1:1000, Abnova). An anti-β-
actin (1:1000, Sigma) was used as a control for protein
loading. Goat anti-rabbit and anti-mouse secondary anti-
bodies (1:3000) were from Cell Signaling.
Results
Enzyme studies
The β-mannosidase enzymatic defect was present both in
the patient's cells (i.e., peripheral blood leukocytes and
Epstein-Barr virus-transformed lymphoid cells) and
plasma (Table 1). Of note, a residual activity of about 7 to
14% was consistently observed in all samples.
These results led us to investigate the β-mannosidase
activity in the asymptomatic family members (see pedi-
gree in Figure 1A). Intermediate levels of β-mannosidase
activity were found in the peripheral blood leukocytes of
both parents, as well as in the youngest brother (II-4) and
sister. The remaining brother (II-3) had rather normal β-
mannosidase activity (Table 1). Determination of β-man-
nosidase activity in plasma and Epstein-Barr virus-trans-
formed lymphoid cells of each relative gave concording
results.
Mutational analysis
As we recently reported [22], sequencing of all exons, the
corresponding exon-intron junctions and the flanking
regions of the MANBA gene showed that the proband was
homozygous for the novel mutation c.1922G>A in exon
14. This mutation, which was also found by sequencing
the cDNA obtained from the patient's cultured lymphoid
cells, caused substitution of arginine 641 by histidine
(p.Arg641His). The proband's parents, his sister and his
youngest brother (II-4) were all heterozygous for this
mutation, in agreement with the intermediate level of β-
mannosidase activity observed in their cells or plasma.
The remaining brother (II-3), who exhibited a normal β-
mannosidase activity level, did not carry the c.1922G>A
mutation. The genetic status of the family members was
confirmed by restriction enzyme analysis using the BbvI
and  MaeIII  enzymes which cleave the wt and mutant
sequence, respectively (Figure 1B). The c.1922G>A muta-
tion was not present among 400 control alleles, and two
www-based prediction programs suggested that the
p.Arg641His change was pathogenic.
The patient was also homozygous for the sequence variant
c.2102C>T (p.Thr701Met) in exon 15 (not shown). This
sequence variant is common in the control population
(frequency 0.49) and is not associated with beta-man-
nosidosis [24].
Expression studies
In order to test whether the c.1922G>A mutation could be
responsible for the β-mannosidase deficiency in the
proband, the wt and mutant enzymes were transiently
expressed in HEK293T cells and the resulting enzyme
Table 1: β-Mannosidase activity in the family.
Patient β-Mannosidase activity
Leukocytes Lymphoid cells Plasma
I-1 (father) 51; 42 20 115; 90
I-2 (mother) 50; 35 16 75; 51
II-1 51; 60 29 127; 102
II-2 4; 8 6; 7 24
II-3 92; 167 ND 160; 115
II-4 68 ND 93; 84
Controls 86 ± 26 (n = 25) 58 ± 19 (n = 4) 174 ± 45 (n = 12)
β-Mannosidase activity was determined in peripheral blood leukocytes, Epstein-Barr virus-transformed lymphoid cells and plasma from family 
members (see Figure 1A). Enzyme activity is expressed as nmol/h.mg of protein (for cells) or nmol/h.ml (for plasma). For patients, the different 
values correspond to independent experiments; for controls, means ± SEM of the indicated number of different samples. ND, not determined.BMC Medical Genetics 2009, 10:84 http://www.biomedcentral.com/1471-2350/10/84
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activity was measured. As a control for transfection effi-
ciency, cells were simultaneously transfected with a vector
encoding the bacterial β-galactosidase (lacZ). The endog-
enous, acid lysosomal β-galactosidase activity was also
assessed as a reference for enzyme activity.
As illustrated in Figure 2, whereas expression of the wt
cDNA sequence led to a considerable increase (about 80-
fold) of β-mannosidase activity, transfection of the vector
carrying the c.1922G>A mutation resulted in a much
lower activity, indicating that this mutation is possibly
disease-causing. However, the enzyme activity generated
by the mutated cDNA remained significantly higher
(about 5.6-fold) than that in untransfected cells. The acid
β-galactosidase activity was similar in all the cell samples
analysed.
The mutant β-mannosidase expression was also character-
ized by Western-blotting, both in the patient's lymphoid
cells and in transiently transfected HEK293T cells (Figure
3). Both the overexpressed and endogenous mutant pro-
tein was detected, showing the same apparent size (about
101 kDa) as the wt enzyme. In HEK293T cells, however,
the mutant β-mannosidase was less abundant than the wt,
suggesting a possible instability of the mutant protein. A
similar conclusion could not be drawn for the endog-
enous enzyme since its expression in lymphoid cells was
very low.
Discussion
Since the identification of the MANBA gene on chromo-
some 4q21-q25, which encodes for the human lysosomal
β-mannosidase, a number of MANBA  mutations have
been described, and attempts to establish genotype-phe-
notype correlations have been proposed [23,25] (see
additional file 1: table for enzyme activity and clinical
phenotype associated by MANBA mutations.). Among the
14  β-mannosidosis-associated sequence variants identi-
fied so far, most are null mutations [9,13,16,18,23-25].
Only three disease-causing missense mutations have been
reported to date, i.e., p.Arg182Trp [17], p.Gly392Glu [9]
and p.Ser505Pro [24], but all three were associated with
null mutations in compound heterozygous patients (see
additional file 1). In this study, we identified a missense
MANBA mutation, which was associated with an uncom-
mon phenotype. This is the first report of a missense
mutation causing deficient activity of β-mannosidase in a
homozygous context, and interestingly, it is also the first
report of a missense mutation resulting in a residual in
vitro enzyme activity of β-mannosidase.
The first hypothesis that proposed MANBA  null muta-
tions could be responsible for the most severe phenotypes
was ruled out when such defects were also shown to be
associated with mild symptoms [9]. It is noteworthy how-
ever, that all the disease-causing mutations identified to
date, totally or almost totally abrogate β-mannosidase
activity (see additional file 1). These observations may
erroneously lead to the conclusion that all β-mannosido-
sis-causing mutations abrogate the β-mannosidase activ-
ity. The present study indicates that this is not the case.
The c.1922G>A (p.Arg641His) mutation was associated
with a residual β-mannosidase activity of about 7% in the
patient's leukocytes, 11% in lymphoblasts and 14% in
plasma. These residual activities appear substantially
higher than those found in cells derived from other β-
mannosidosis patients, which usually ranged between 0
and 4% of the control (additional file 1; see also [23]).
Moreover, the enzyme activity measured for this mutant
β-mannosidase expressed in eukaryotic cells represented
7% of the wt, which is higher than that reported when
three different mutant enzymes (p.Arg182Trp,
p.Gly392Glu and p.Ser505Pro) were expressed in mam-
malian cells [24]. Thus, although markedly reduced, the
β-mannosidase activity of the p.Arg641His mutant was
Segregation of the c.1922G>A MANBA mutation in the family Figure 1
Segregation of the c.1922G>A MANBA mutation in 
the family. A, Family pedigree. The arrow denotes the 
proband. Genetic status for the c.1922G>A mutation is indi-
cated by black and white symbols. B, Restriction enzyme 
analysis of exon 14 in the patient, his family and three control 
subjects (denoted C1 to C3). PCR-amplified exon 14 (a 423 
bp fragment) was digested with MaeIII or BbvI and analyzed 
by gel electrophoresis.BMC Medical Genetics 2009, 10:84 http://www.biomedcentral.com/1471-2350/10/84
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not totally abolished. The c.1922G>A mutation leads to
the replacement of an arginine by a histidine
(p.Arg641His). Arginine in this position is conserved in
most mammals, zebrafish, fruitfly, mosquito and worm,
but is replaced by a serine in chimpanzee, by glutamine in
opossum and by methionine in frog. Arginine and histi-
dine share basic properties, and this change may allow for
some residual activity. Further studies are needed to
understand more about how this substitution affects the
MANBA protein.
Despite its residual activity, the p.Arg641His mutant
enzyme is associated with a severe clinical presentation
([22]; see also additional file 1). It has been proposed that
the nature of the MANBA mutation dictates the severity of
the  β-mannosidosis phenotype. Null mutations could
have been responsible for the most severe phenotypes
while missense mutations could have led to the mildest
ones. However, recent findings have challenged this view,
by showing that null mutations are sometimes associated
with mild phenotypes [23]. On the other hand, some mis-
sense mutations completely abrogate the enzyme activity,
and thus could not explain mild phenotypes [24]. The
present study further extends this lack of genotype-pheno-
Enzymatic activities in transfected HEK293T cells Figure 2
Enzymatic activities in transfected HEK293T cells. A, Acid β-mannosidase, acid β-galactosidase and E. coli β-galactosi-
dase activities were measured in lysates of untransfected HEK293T cells and cells over-expressing either the wild-type (pCS2-
MANBA) or the mutant (pCS2-MANBA-p.Arg641His) acid β-mannosidase. Activities are expressed as nmol/h.mg protein, and 
are means ± SEM of 3 independent experiments performed in duplicate. The β-mannosidase activity was similar in untrans-












































Expression of endogenous and overexpressed β-mannosi- dase Figure 3
Expression of endogenous and overexpressed β-man-
nosidase. Lysates of control and patient's lymphoid cells 
(100 μg protein), as well as HEK293T cells transiently trans-
fected with a vector encoding wild-type (pCS2-MANBA) or 
mutant (pCS2-MANBA-p.Arg641His) β-mannosidase (25 μg 
protein), were assessed for β-mannosidase expression by 
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type correlation by showing that a mutation that does not
fully abolish the enzyme activity is associated with a
severe form of the disease (the possibility that the
observed residual enzyme activity may exist only towards
the artificial fluorogenic substrate, but not the natural
substrate, cannot be excluded). We suggest that the level
of enzymatic activity is not sufficient to predict the clinical
severity, and that, as previously concluded [23,24] other,
epigenetic or environmental factors contribute to the clin-
ical heterogeneity of β-mannosidosis. Alternatively, the
p.Arg641His mutant may represent the first report of β-
mannosidase pseudodeficiency. Although it has never
been reported so far for this particular enzyme, pseudode-
ficiencies of other lysosomal hydrolases are well known
[26]. Enzyme residual activities of previously reported
pseudodeficiency cases can be quite variable. It is there-
fore difficult to use the degree of residual activity as a sole
means to differentiate between a pseudodeficiency and a
disease-causing defect. In the present case, the hypothesis
of a pseudodeficiency would be in accordance with the
fact that no oligosacchariduria was detected [22]. If so, the
patient's symptomatology would not be the result of the
observed reduced enzyme activity but a yet unkown cause.
Conclusion
The present analysis of the c.1922G>A MANBA mutation
underlines the lack of genotype-phenotype correlation in
beta-mannosidosis. The hypothesis that this mutation
leads to a pseudodeficiency cannot yet be ruled out.
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